New Delhi: Pharma firm Cadila Healthcare Ltd posted 40.56 per cent jump in consolidated net profit to Rs 390.91 for the second quarter ended on September 30, 2015-16.
"The Group has posted a net profit after taxes, minority interest and share in profit of associates of Rs 390.91 crore for the quarter ended September 30, 2015 as compared to Rs 278.09 crore for the quarter ended September 30, 2014," Cadila said in a BSE filing today.
Its total income has increased from Rs 2,122.61 crore for the quarter ended September 30 in the 2014-15 fiscal to Rs 2,483.19 crore in the second quarter of the current fiscal.
The company has posted standalone net profit of Rs 614.08 crore for the quarter ended September 30, 2015 as compared to Rs 365,61 crore in the year-ago period.
The standalone total income of the company has increased from Rs 1,396.6 crore for the year-ago quarter to Rs 1,976.45 crore July-September quarter.
In the consolidated results, other operating income for quarter ended on September 30, includes consideration Rs 20.03 crore ($3 million) received by Zydus Pharmaceuticals (USA) Inc. a wholly owned subsidiary company, on sale and transfer of ownership interest in certain Abbreviated New Drug Applications (ANDAs) for generic drug products.
The six month period, April-September, includes the consideration of Rs 86.7 crore ($13.5 million) on that account.